PSTV - Plus Therapeutics Inc Stock Price, Fair Value and News

$0.60+0.01 (+1.69%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

PSTV Price Action

Last 30 days

15.4%

Last 90 days

33.3%

Trailing 12 Months

-55.2%

PSTV RSI Chart

PSTV Valuation

Market Cap

82.5M

Price/Earnings (Trailing)

-4.01

Price/Sales (Trailing)

15.68

Price/Free Cashflow

-5.22

PSTV Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PSTV Fundamentals

PSTV Revenue

Revenue (TTM)

5.3M

Rev. Growth (Yr)

-4.05%

Rev. Growth (Qtr)

0.5%

PSTV Earnings

Earnings (TTM)

-20.6M

Earnings Growth (Yr)

-53.9%

Earnings Growth (Qtr)

-185.87%

PSTV Profitability

Return on Equity

-407.12%

Return on Assets

-110.21%

Free Cashflow Yield

-19.17%

PSTV Investor Care

Shares Dilution (1Y)

2230.75%

Diluted EPS (TTM)

-1.83

PSTV Alerts

1 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	5.2M	5.3M	5.3M	0
2024	5.1M	5.4M	5.6M	5.8M
2023	0	0	0	0
2022	0	0	0	0
2021	0	0	0	0
2020	0	0	0	303.0K
2019	2.8M	0	2.4M	3.2M
2018	3.6M	4.0M	3.1M	3.0M
2017	6.2M	5.0M	4.4M	3.7M
2016	6.7M	6.6M	6.7M	6.7M
2015	4.8M	5.7M	6.9M	6.0M
2014	6.0M	6.1M	5.0M	5.0M
2013	9.6M	8.5M	8.8M	7.3M
2012	8.1M	7.6M	6.8M	8.7M
2011	6.8M	7.1M	8.3M	8.0M
2010	0	8.5M	8.1M	7.7M
2009	0	0	0	8.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Plus Therapeutics Inc

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

CEO	Dr. Marc H. Hedrick M.B.A., M.D.
WEBSITE	https://plustherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	17

Plus Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Plus Therapeutics Inc? What does PSTV stand for in stocks?

PSTV is the stock ticker symbol of Plus Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Plus Therapeutics Inc (PSTV)?

As of Wed Dec 03 2025, market cap of Plus Therapeutics Inc is 82.46 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PSTV stock?

You can check PSTV's fair value in chart for subscribers.

Is Plus Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PSTV is over valued or under valued. Whether Plus Therapeutics Inc is cheap or expensive depends on the assumptions which impact Plus Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PSTV.

What is Plus Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, PSTV's PE ratio (Price to Earnings) is -4.01 and Price to Sales (PS) ratio is 15.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PSTV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Plus Therapeutics Inc's stock?

In the past 10 years, Plus Therapeutics Inc has provided -0.672 (multiply by 100 for percentage) rate of return.